Brokerages Anticipate Y-mAbs Therapeutics, Inc (YMAB) to Announce -$0.33 Revenue Per Share

Brokerages Anticipate Y-mAbs Therapeutics, Inc (YMAB) to Announce -$0.33 Revenue Per Share

Wall Street analysts predict that Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) will report earnings of ($0.33) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Y-mAbs Therapeutics’ earnings. The highest EPS estimate is ($0.30) and the lowest is ($0.36). The company is scheduled to issue its next quarterly earnings report on Tuesday, February 12th.

On average, analysts expect that Y-mAbs Therapeutics will report full-year earnings of ($1.41) per share for the current fiscal year, with EPS estimates ranging from ($1.44) to ($1.38). For the next fiscal year, analysts expect that the company will report earnings of ($1.37) per share, with EPS estimates ranging from ($1.49) to ($1.25). Zacks’ earnings per share averages are a mean average based on a survey of analysts that that provide coverage for Y-mAbs Therapeutics.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its earnings results on Tuesday, November 13th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.09).

A number of equities research analysts recently issued reports on YMAB shares. BTIG Research started coverage on Y-mAbs Therapeutics in a research note on Tuesday, October 16th. They issued a “buy” rating and a $35.00 target price on the stock. Cowen reaffirmed a “buy” rating on shares of Y-mAbs Therapeutics in a research note on Tuesday, October 16th. Canaccord Genuity started coverage on Y-mAbs Therapeutics in a research note on Tuesday, October 16th. They issued a “buy” rating and a $30.00 target price on the stock. Bank of America started coverage on Y-mAbs Therapeutics in a research note on Tuesday, October 16th. They issued a “buy” rating and a $26.00 target price on the stock. Finally, Zacks Investment Research raised Y-mAbs Therapeutics from a “hold” rating to a “buy” rating and set a $23.00 target price on the stock in a research note on Sunday, January 6th. Five analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and an average price target of $28.50.

Several institutional investors have recently modified their holdings of the business. BlackRock Inc. lifted its stake in shares of Y-mAbs Therapeutics by 2,178.9% during the 4th quarter. BlackRock Inc. now owns 341,831 shares of the company’s stock worth $6,952,000 after purchasing an additional 326,831 shares during the period. Strs Ohio purchased a new position in shares of Y-mAbs Therapeutics during the 4th quarter worth $38,000. Vanguard Group Inc purchased a new position in shares of Y-mAbs Therapeutics during the 3rd quarter worth $2,260,000. Vanguard Group Inc. purchased a new position in shares of Y-mAbs Therapeutics during the 3rd quarter worth $2,260,000. Finally, Point72 Asset Management L.P. purchased a new position in shares of Y-mAbs Therapeutics during the 3rd quarter worth $133,000. 22.38% of the stock is currently owned by institutional investors.

YMAB stock traded up $0.17 on Friday, reaching $20.69. The company had a trading volume of 7,217 shares, compared to its average volume of 34,529. Y-mAbs Therapeutics has a 1 year low of $15.17 and a 1 year high of $31.00.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody therapeutic products for cancer treatment in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system/leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.

Featured Story: Do Tariffs Work?

Get a free copy of the Zacks research report on Y-mAbs Therapeutics (YMAB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Related posts

Leave a Comment